Raymond James Financial Inc. Invests $943,000 in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Raymond James Financial Inc. bought a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,592 shares of the life sciences company’s stock, valued at approximately $943,000. Raymond James Financial Inc. owned about 0.05% of Integra LifeSciences as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of IART. Charles Schwab Investment Management Inc. grew its holdings in shares of Integra LifeSciences by 10.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company’s stock valued at $23,759,000 after buying an additional 103,291 shares during the last quarter. Access Investment Management LLC purchased a new stake in Integra LifeSciences during the 4th quarter valued at about $4,416,000. Leeward Investments LLC MA grew its stake in Integra LifeSciences by 7.8% during the 4th quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company’s stock valued at $9,197,000 after purchasing an additional 29,402 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Integra LifeSciences by 5.5% in the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock worth $9,603,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter worth about $180,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Trading Down 2.4 %

Shares of IART stock opened at $19.57 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $34.79. The stock has a market capitalization of $1.51 billion, a P/E ratio of -217.42, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a 50 day moving average price of $23.37 and a 200 day moving average price of $22.27.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same period last year, the business posted $0.89 earnings per share. Integra LifeSciences’s revenue was up 11.5% compared to the same quarter last year. Equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.